Drug and cosmetic act amendments?
Searching the Web
Drug and Cosmetics Act amendments India 2024 2025 latest
Searching the Web
Drugs Medical Devices Cosmetics Bill India 2023 amendments updates
Reading Web Page
https://www.majmudarindia.com/drugs-medical-devices-and-cosm…
Here is a structured overview of the Drugs and Cosmetics Act, 1940 - Amendments and Current Status:
Drugs and Cosmetics Act, 1940 - Amendments Overview
Original Act (1940)
Enacted to regulate the import, manufacture, distribution, and sale of drugs and cosmetics in India. Administered by the Drug Controller General of India (DCGI) through the Central Drugs Standard Control Organisation (CDSCO).
Major Historical Amendments
| Year | Key Change |
|---|---|
| 1955 | Added provisions for Ayurvedic, Siddha, and Unani drugs |
| 1960 | Cosmetics brought under a separate chapter |
| 1964 | Strengthened import control provisions |
| 1982 | Tougher penalties for adulterated/spurious drugs; Schedule H introduced for prescription-only drugs |
| 1986 | Provisions for blood and blood products added |
| 1999 | Stricter norms for clinical trials introduced |
| 2008 | Amendment Act expanded scope of "spurious drugs" and enhanced penalties |
Drugs and Cosmetics (Amendment) Act, 2008 - Key Points
- Redefined spurious drugs to include those with incorrect labelling
- Introduced mandatory reporting of adverse drug reactions
- Strengthened provisions for clinical trials
- Enhanced punishment - imprisonment up to life for offences involving counterfeit drugs causing death
New Drugs and Clinical Trials (NDCT) Rules, 2019
Not a direct amendment to the Act but a significant regulatory update:
- Replaced the earlier clinical trial rules
- Defined new drugs, investigational new drugs, and orphan drugs
- Time-bound approvals (12 weeks for new drug applications)
- Waiver of local clinical trials if drug is already approved in specified reference countries
Medical Devices Rules, 2017 (& 2020 Amendment)
- Carved out a separate regulatory pathway for medical devices (previously classified as "drugs")
- Created a risk-based classification system (Class A, B, C, D)
- 2020 amendment expanded definitions and compliance timelines
Jan Vishwas (Amendment of Provisions) Act, 2023
- Decriminalized certain minor offences under the Drugs and Cosmetics Act
- Converted some criminal penalties to civil/monetary penalties to reduce compliance burden
- Government is examining further provisions that can be decriminalized
Most Significant Development: Drugs, Medical Devices and Cosmetics Bill, 2023
This draft Bill, published by the Ministry of Health and Family Welfare (MoHFW), is intended to fully replace the 84-year-old Drugs and Cosmetics Act, 1940. As of mid-2024, it was in public consultation stage.
Key Features of the 2023 Bill
1. Structural Overhaul
- Separate chapters for drugs, medical devices, and cosmetics (no longer lumped together)
- Medical devices treated as a distinct category - not a subset of drugs
- Independent Medical Devices Technical Advisory Board and Medical Devices Testing Centres
2. Strengthened Regulatory Bodies
- New Drugs, Medical Devices and Cosmetics Consultative Committee (DMDCCC) chaired by DCGI
- Quasi-judicial authorities to adjudicate procedural and minor offences
- Issuance of improvement notices before initiating proceedings (giving manufacturers a chance to correct deficiencies)
3. Clinical Trials
- Better regulation of clinical trials for new drugs
- Clinical investigation provisions for investigational medical devices
- Clinical performance evaluation for new in vitro diagnostic (IVD) medical devices
- Emergency use and accelerated approval provisions for new drugs and medical devices
4. E-Pharmacies & Digital Provisions
- Explicit regulation of online/e-pharmacy sales
- Digital interventions for innovation, data management, and data analytics
5. Recall Provisions
- Formal framework for recall of drugs, cosmetics, and medical devices (previously absent)
6. AYUSH
- More comprehensive framework for Ayurveda, Yoga, Unani, Siddha, Homeopathy (AYUSH) products
7. Penalties - Significantly Enhanced
- Fine: greater of INR 15 lakh (~US$18,000) or 3x the value of confiscated drugs
- Life imprisonment for importing/manufacturing sub-standard or spurious drugs likely to cause death or grievous bodily harm
- In case of adverse consumer impact, fine amount to be paid to the affected consumer or heirs
Current Status (as of mid-2026)
- The 2023 Draft Bill underwent public stakeholder consultation
- As of June 2024 (CDSCO update), the Ministry was incorporating feedback from industry associations
- The Bill has not yet been passed into law - the Drugs and Cosmetics Act, 1940 continues to be in force alongside its Rules and ancillary regulations
- Revised Schedule M (Good Manufacturing Practices) was also being updated in parallel
Other Active Regulations Running Alongside the Act
- Drugs and Cosmetics Rules, 1945 (frequently amended)
- New Drugs and Clinical Trials Rules, 2019
- Medical Devices Rules, 2017
- Drugs (Prices Control) Order, 2013 (under Essential Commodities Act)
- Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954
If you need details on any specific amendment, a particular schedule (Schedule H, H1, X), licensing provisions, or state vs. central licensing - let me know.
This is a shared conversation. Sign in to Orris to start your own chat.